Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Software and Reagents Expand Productivity, Efficiency for Targeted Quantitative Proteomics

By Biotechdaily staff writers
Posted on 26 Jun 2008
New software tools are being developed to address the needs of scientists in industry and academia who are seeking to quantify many specific proteins and peptides in complex biologic samples. More...
Thousands of proteins may be present in any specific laboratory sample; however, scientists are often most willing to examine the subset of those that are typically lower in abundance and are changing in response to a disease.

Applied Biosystems (Foster City, CA, USA), an Applera Corp. (Alameda, CA, USA) business, and its joint-venture partner, MDS Analytical Technologies (Concord, Ontario, Canada), a business unit of MDS, Inc., announced the availability of a suite of integrated mass spectrometry-based solutions for conducting targeted quantitative proteomics studies. Designed for Applied Biosystems/MDS Analytical Technologies' triple quadrupole and hybrid triple quadrupole/linear ion trap mass spectrometry systems, these solutions include software packages and consumables that enable scientists to quantify proteins more effectively in biomarker research or cell biology.

Targeted mass spectrometry is emerging as a powerful tool for these quantitative assays, however major challenges remain. The need for higher-order multiplexing, improved reproducibility, and more rapid assay development for these protein panels is critical for scientists to continue to drive forward their biomarker initiatives in a streamlined, efficient way. Applied Biosystems/MDS Analytical Technologies' targeted quantitative proteomics solutions can address these challenges because they are designed to deliver consistency along with simplified, one-touch accessibility to sophisticated technology across the entire workflow.

These new tools include: mTRAQ reagents, which are chemical labeling kits for use in targeted proteomics experiments using multireaction monitoring (MRM) analysis that can be used to create global internal standards to provide an internal reference for every protein, peptide, and post-translational modification in a sample, in a simple, one-hour step. Based on proprietary Applied Biosystems technology, mTRAQ reagents are designed to improve analytic reproducibility for quantitative experiments without the need for expensive, custom, synthetic peptides.

Scheduled Multiple Reaction Monitoring is a feature that focuses instrument cycle scans for specific analytes based on the timeframe that those analytes will be entering the instrument. In proteomics, this means the instrument can scan up to 10 times more peptides with better analytic precision and yielding more information about each one. The Scheduled MRM Algorithm is part of Applied Biosystems/MDS Analytical Technologies' updated operating system, Analyst 1.5 software, which powers its mass spectrometry systems.

MRMPilot software is a new software program for use with Applied Biosystems/MDS Analytical Technologies Q TRAP systems that enable rapid development of robust MRM assays for peptides and proteins utilizing data acquired during discovery experiments. MRMPilot Software automatically builds MRM assays and utilizes the unique Midas Workflow of the Q TRAP system for more seamless and far more efficient transition from discovery to validation. These assays complement existing widely used antibody-based assays, while requiring up to 10-fold less time to develop and eliminating the need for purified proteins.

MultiQuant software is a new software package for use with Applied Biosystems/MDS Analytical Technologies mass spectrometers that processes MRM data for quantitative information. The software enables the efficient processing of many analytes and samples at the same time, with an emphasis on the requirements for processing protein/peptide quantitative workflows.

Applied Biosystems develops and markets instrument systems, software, consumables, and services for the life science market. Through a joint venture with MDS Analytical Technologies, the company is providing complete workflows for the mass spectrometry market, based on industry-leading platforms, software and new application workflows

MDS Analytical Technologies is a newly established MDS, Inc., business unit and is comprised of two main lines of business. The Sciex product range offers mass spectrometry systems through its joint ventures with two leading analytic instrumentation and life sciences companies, Applied Biosystems, a business of Applera Corp., and PerkinElmer, Inc. (Waltham, MA, USA). MDS' product range includes high-performance bioanalytic measurement systems that accelerate and improve drug discovery and other life sciences research.


Related Links:
Applied Biosystems
MDS Analytical Technologies

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.